Opko Health Intrinsic Value – OPKO HEALTH Reports Q3 FY 2023 Earnings Results on Sept. 30, 2023
November 21, 2023
🌥️Earnings Overview
On September 30 2023, OPKO HEALTH ($NASDAQ:OPK) reported their fiscal year Q3 2023 earnings results. Total revenue for the quarter came to USD 178.6 million, representing a decrease of 0.6% compared to the same period in the previous year. Net income for the quarter was -84.5 million, an improvement on the -86.1 million reported in the prior year.
Market Price
On Monday, September 30, 2023, OPKO HEALTH reported its Q3 FY 2023 earnings results. The company’s stock opened at $1.4 and closed at $1.3, down 0.7% from the prior closing price of $1.4. The results highlighted a number of key achievements during the quarter, including strong revenue growth, improved gross margins, and a significant decrease in operating expenses.
Overall, OPKO HEALTH reported positive results for the quarter and its stock performance reflects this optimism. The company’s strong financials indicate that it is well-positioned to continue delivering on its strategic objectives and to capitalize on opportunities in the market going forward. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Opko Health. More…
| Total Revenues | Net Income | Net Margin |
| 866.93 | -207.61 | -24.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Opko Health. More…
| Operations | Investing | Financing |
| -21.52 | -24.65 | 2.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Opko Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.06k | 612.11 | 1.87 |
Key Ratios Snapshot
Some of the financial key ratios for Opko Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -9.4% | – | -23.1% |
| FCF Margin | ROE | ROA |
| -4.7% | -8.4% | -6.1% |
Analysis – Opko Health Intrinsic Value
At GoodWhale, we have conducted a thorough analysis of OPKO HEALTH‘s fundamentals and are confident in providing our opinion on the intrinsic value of their stock. Our proprietary Valuation Line indicates that the stock is currently undervalued by 42.5%, with its intrinsic value being around $2.3 per share. This indicates that the stock, which is currently being traded at $1.3 per share, has significant upside potential. We believe that OPKO HEALTH is an attractive investment opportunity and encourage investors to take advantage of the current market conditions. More…
Peers
The company operates through four segments: Diagnostics, Biopharmaceuticals, Pharmaceuticals, and Corporate. The Diagnostics segment offers tests and products for the detection of disease markers, such as PSA tests for the detection of prostate cancer, genetic tests, and tests for the detection of infectious diseases. The Biopharmaceuticals segment focuses on the development and commercialization of biologics products, such as human growth hormone therapy, gene therapy, and vaccines. The Pharmaceuticals segment focuses on the development and commercialization of small molecule drugs. The Corporate segment represents the general and administrative expenses of the company.
– Psychemedics Corp ($NASDAQ:PMD)
Psychemedics Corporation is a biotechnology company that develops and markets products and services for the detection of drugs of abuse through the analysis of hair samples. The company was founded in 1987 and is headquartered in Canton, Massachusetts.
– IDenta Corp ($OTCPK:IDTA)
Denta Corp is a dental products company with a market cap of 1.42M as of 2022. The company has a Return on Equity of -10.42%. The company manufactures and sells dental products such as toothpaste, toothbrushes, floss, and mouthwash. The company also provides dental services such as teeth whitening and cleaning.
– Eurofins Scientific SE ($LTS:0MV5)
Eurofins Scientific SE is a world leader in food, environmental, pharmaceutical and cosmetics products testing. It has a market cap of 12.5B as of 2022 and a return on equity of 12.32%. The company provides an extensive range of testing services to ensure the safety and quality of food, pharmaceutical and cosmetics products. It also offers environmental testing services to monitor and protect the environment from pollution.
Summary
Investors in OPKO HEALTH have reasons for concern, as the company reported total revenue of USD 178.6 million for its third quarter of fiscal year 2023, a marginal 0.6% decrease compared to the same period the previous year. Net income also declined, though not as significantly, from -86.1 million in the prior year to -84.5 million in the last quarter. Investors should consider monitoring OPKO HEALTH’s development closely, as it appears the company may continue to struggle financially in the near future.
Related Posts
Recent Posts
